Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Probionic paraprobiotic
- Development stage
- Preclinical
- Lead developer
- Probionic
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
Probionic's paraprobiotic is a heat-treated, non-viable bacterial preparation derived from the *Lactobacillus sakei* Probio65 strain. As a paraprobiotic (also referred to as a "ghost probiotic" or "tyndallized probiotic"), it consists of inactivated microbial cells that retain biological activity through their structural components, such as cell wall fragments and metabolites. Developed by the South Korean company Probionic, this preparation is primarily targeted at modulating immune responses and maintaining skin and gut health. It is utilized in commercial products like Lactopy and Boyan-I, with research focusing on its efficacy in treating atopic dermatitis, inflammatory bowel disease, and metabolic disorders. The heat-treatment process ensures stability and safety, particularly for individuals with compromised intestinal barriers, while still providing the immunomodulatory benefits associated with the parent strain.
- Brand names
- LactopyBoyan-ICubiome
- Other names
- heat-treated Lactobacillus sakei Probio65non-viable Probio65heat-killed Probio65paraprobiotics-Probionic-paraprobiotic
02
Targets
CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on Probionic paraprobiotic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Probionic paraprobiotic.